Cannabis Report
Home > Boards > US OTC > Biotechs > CYTODYN INC (CYDY)

N =50 is a compromise from statistical significance

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
pearsby09 Member Profile
Member Level 
Followed By 29
Posts 4,523
Boards Moderated 0
Alias Born 04/29/16
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 9/20/2018 5:06:23 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/12/2018 4:32:34 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 9/10/2018 3:50:45 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/7/2018 6:26:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/7/2018 6:25:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/7/2018 6:24:14 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 9/7/2018 5:31:21 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/4/2018 4:33:16 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 8/31/2018 4:35:00 PM
Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425) Edgar (US Regulatory) - 8/31/2018 4:33:10 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/28/2018 4:34:51 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/23/2018 7:33:49 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2018 5:33:42 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/14/2018 5:32:23 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/13/2018 4:39:40 PM
Annual Report (10-k) Edgar (US Regulatory) - 7/27/2018 5:03:58 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/12/2018 4:32:55 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/27/2018 9:02:31 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/22/2018 5:02:40 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/15/2018 7:49:45 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/15/2018 7:44:52 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 6:04:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 6:03:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:59:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:59:49 PM
pearsby09 Member Level  Friday, 11/10/17 01:27:26 PM
Re: None
Post # of 29107 
N =50 is a compromise from statistical significance to clinical significance, and even 50 is not a compelling data base for any analysis. PRO 140 IMO, will be the eighth choice on an ever revolving HAART approach. Physicians will be very reticent in adopting a N=50 drug before trying all the established HAART combinations. Habit and comfort precedes PRO 140, especially with a N=50 data base.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist